Internal Medicine, Rheumatology · Hoover, AL
NPI
1811105398
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
5356 Stadium Trace Pkwy Ste 200
Hoover, AL, 35244
Phone (205) 444-4858
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.8M
282,431 services
Medicare patients, 2024
292
Average age 73
Drug cost, 2024
$5.9M
4,867 prescriptions
Company payments, 2025
$52K
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Elizabeth L Perkins was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 140,000 times for 34 patients. In total Elizabeth L Perkins billed 282,431 services in 37 codes, and Medicare paid $3.8M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-26.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 140,000 | 34 | $3.62 | $506K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 19,775 | 27 | $33.79 | $668K |
| J3247 Injection, secukinumab, intravenous, 1 mg | Office | 14,399 | 13 | $13.76 | $198K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 11,418 | 14 | $9.10 | $104K |
| J0897 Injection, denosumab, 1 mg | Office | 9,660 | 89 | $20.30 | $196K |
| J3245 Injection, tildrakizumab, 1 mg | Office | 6,700 | 20 | $106.92 | $716K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 5,730 | 17 | $24.30 | $139K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 2,532 | 61 | $0.22 | $557 |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 2,243 | 47 | $0.09 | $203 |
| 96401 Chemotherapy Administration | Office | 1,038 | 152 | $49.62 | $52K |
| Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 955 | 14 | $23.56 | $22K |
| 96413 Chemotherapy Administration | Office | 633 | 84 | $88.84 | $56K |
| 96375 Injection Administration | Office | 611 | 73 | $10.63 | $6,495 |
| 99214 Office E&M - Established | Office | 541 | 253 | $86.63 | $47K |
| 99215 Office E&M - Established | Office | 303 | 162 | $121.10 | $37K |
By year: 2022 $3.3M for 242,969 services; 2023 $3.2M for 262,117 services; 2024 $3.8M for 282,431 services.
Medicare prescription drug claims, 2024
In 2024, the drug Elizabeth L Perkins prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 583 prescriptions and refills. In total Elizabeth L Perkins wrote 4,867 Medicare prescriptions that cost $5.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 583 | 1,489 | 162 | $45K |
| Methotrexate Methotrexate Sodium | 464 | 932 | 116 | $20K |
| Tramadol Hcl Generic | 266 | 284 | 61 | $2,373 |
| Rinvoq Upadacitinib | 264 | 272 | 30 | $1.7M |
| Prednisone Generic | 261 | 265 | 122 | $1,377 |
| Gabapentin Generic | 258 | 470 | 58 | $3,137 |
| Celecoxib Generic | 212 | 335 | 52 | $8,698 |
| Diclofenac Sodium Generic | 187 | 369 | 52 | $4,335 |
| Duloxetine Hcl Generic | 172 | 430 | 54 | $5,703 |
| Tizanidine Hcl Generic | 170 | 311 | 53 | $1,233 |
| Humira(Cf) Pen Adalimumab | 122 | 122 | 15 | $1.1M |
| Meloxicam Generic | 119 | 205 | 38 | $588 |
| Leflunomide Generic | 105 | 239 | 29 | $12K |
| Omeprazole Generic | 102 | 235 | 30 | $1,208 |
| Tramadol Hcl-Acetaminophen Tramadol Hcl/Acetaminophen | 96 | 99 | 16 | $1,986 |
Brand drugs: 872 claims; generic drugs: 3,975 claims; opioid claims: 402.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Elizabeth L Perkins $52K ($52K in general payments such as food, travel and fees) from 26 companies. The largest payer was Novartis Pharmaceuticals Corporation with $15K.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 30 | $15K |
| UCB, Inc. UCB.BR | 38 | $11K |
| Abbvie Inc. ABBV | 35 | $10K |
| Lilly USA, LLC LLY | 8 | $4,809 |
| Janssen Biotech, Inc. JNJ | 19 | $3,352 |
| E.R. Squibb & Sons, L.L.C. BMY | 14 | $3,013 |
| Amgen Inc. AMGN | 49 | $1,134 |
| Ucb Sa UCB.BR | 1 | $920 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $375 |
| Pfizer Inc. PFE | 19 | $363 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.